Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
- PMID: 35539091
- PMCID: PMC9075752
- DOI: 10.1039/c9ra08954c
Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation
Erratum in
-
Correction: Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation.RSC Adv. 2020 Jan 31;10(9):4927. doi: 10.1039/d0ra90007a. eCollection 2020 Jan 29. RSC Adv. 2020. PMID: 35503286 Free PMC article.
Abstract
Both the kinase MET and the WNT signaling pathway are attractive targets in cancer therapy, and synergistic effects have previously been observed in animal models upon simultaneous inhibition. A strategy towards a designed multiple ligand of MET and WNT signaling is pursued based on the two hetero biaryl systems present in both the MET inhibitor tepotinib and WNT signaling inhibitor TC-E 5001. Initial screening was conducted to find the most suitable ring systems for further optimization, whereas a second screen explored modifications towards pyridazinones and triazolo pyridazines. Up to 54% reduction of WNT signaling activity at 10 μM concentration was achieved, however, only low affinities towards MET were observed. Overall, the thiophene substituted pyridazinone 40 was the best dual MET and WNT signaling inhibitor, with a 17% and 19% reduction of activity, respectively. Although further optimizations are needed to achieve more potent dual inhibitors, the strategy presented herein can be valuable towards the development of a dual inhibitor of MET and WNT signaling.
This journal is © The Royal Society of Chemistry.
Conflict of interest statement
There are no conflicts to declare.
Figures






Similar articles
-
Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.ACS Med Chem Lett. 2017 Jul 18;8(8):830-834. doi: 10.1021/acsmedchemlett.7b00172. eCollection 2017 Aug 10. ACS Med Chem Lett. 2017. PMID: 28835797 Free PMC article.
-
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.Bioorg Med Chem Lett. 2015 Apr 1;25(7):1597-602. doi: 10.1016/j.bmcl.2015.02.002. Epub 2015 Feb 16. Bioorg Med Chem Lett. 2015. PMID: 25736998
-
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.Cancer Biol Ther. 2014 Sep;15(9):1129-41. doi: 10.4161/cbt.29451. Epub 2014 Jun 11. Cancer Biol Ther. 2014. PMID: 24914950 Free PMC article.
-
Azolo[d]pyridazinones in medicinal chemistry.Future Med Chem. 2021 Feb;13(3):287-311. doi: 10.4155/fmc-2020-0234. Epub 2020 Dec 4. Future Med Chem. 2021. PMID: 33275029 Review.
-
Dysregulation of Wnt/β-catenin signaling by protein kinases in hepatocellular carcinoma and its therapeutic application.Cancer Sci. 2021 May;112(5):1695-1706. doi: 10.1111/cas.14861. Epub 2021 Apr 6. Cancer Sci. 2021. PMID: 33605517 Free PMC article. Review.
Cited by
-
Diverse Pharmacological Potential of Pyridazine Analogs against Various Diseases.Med Chem. 2024;20(3):245-267. doi: 10.2174/1573406419666230913102835. Med Chem. 2024. PMID: 37711126 Review.
-
Therapeutic Target Identification and Inhibitor Screening against Riboflavin Synthase of Colorectal Cancer Associated Fusobacterium nucleatum.Cancers (Basel). 2022 Dec 19;14(24):6260. doi: 10.3390/cancers14246260. Cancers (Basel). 2022. PMID: 36551744 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous